Fonar Corp (NASDAQ: FONR)

Sector: Healthcare Industry: Diagnostics & Research CIK: 0000355019
Market Cap 114.64 Mn
P/B 0.66
P/E 16.42
P/S 1.09
ROIC (Qtr) 3.30
Div Yield % 0.00
Rev 1y % (Qtr) 4.34
Total Debt (Qtr) 39.93 Mn
Debt/Equity (Qtr) 0.23

About

FONAR Corporation, with its ticker symbol FONR, operates in the medical equipment industry, specifically focusing on the design, manufacturing, selling, and servicing of magnetic resonance imaging (MRI) scanners. Founded in 1978, FONAR has established itself as a pioneer in the MRI scanner market, offering a unique product line that provides diagnostic advantages over traditional MRI scanners. FONAR's primary business activity is the medical equipment segment, which is conducted directly through the company. This segment is dedicated to the design,...

Read more

Price action

Investment thesis

Bull case

  • Healthy cash reserves of 54.28M provide 13.87x coverage of short-term debt 3.91M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 210.83M provides 5.28x coverage of total debt 39.93M, indicating robust asset backing and low credit risk.
  • Operating cash flow of 11.30M provides exceptional 607x coverage of interest expenses 18611, showing strong debt service capability.
  • Tangible assets of 210.83M provide exceptional 24.87x coverage of deferred revenue 8.48M, showing strong service capability backing.
  • Robust free cash flow of 7.44M exceeds capital expenditure of 3.85M by 1.93x, indicating strong organic growth funding capability.

Bear case

  • Operating cash flow of 11.30M barely covers its investment activities of (4.35M), with a coverage ratio of -2.60, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of (4.35M) provide weak support for R&D spending of 1.71M, which is -2.55x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of 11.30M provides insufficient coverage of deferred revenue obligations of 8.48M, which is 1.33x, raising concerns about future service delivery capabilities.
  • High receivables of 87.94M relative to inventory of 2.75M (32 ratio) suggests aggressive credit terms or collection difficulties, potentially masking revenue quality issues.
  • Operating earnings of 10.35M show weak coverage of depreciation charges of 3.79M, with a 2.73 ratio indicating high capital intensity and potential reinvestment needs.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Diagnostics & Research
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 TMO Thermo Fisher Scientific Inc. 234.48 Bn 35.69 5.36 35.68 Bn
2 DHR Danaher Corp /De/ 171.11 Bn 48.85 7.05 16.86 Bn
3 IDXX Idexx Laboratories Inc /De 57.62 Bn 56.08 13.83 1.09 Bn
4 IQV Iqvia Holdings Inc. 42.37 Bn 33.03 2.66 15.19 Bn
5 A Agilent Technologies, Inc. 42.16 Bn 32.36 6.07 3.35 Bn
6 NTRA Natera, Inc. 31.64 Bn -102.32 14.95 0.18 Bn
7 MTD Mettler Toledo International Inc/ 30.89 Bn 36.96 7.84 2.21 Bn
8 WAT Waters Corp /De/ 23.59 Bn 36.37 7.60 1.49 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.45 2.82
EV to Cash from Ops. EV/CFO 8.61 19.55
EV to Debt EV to Debt 2.43 54.87
EV to EBIT EV/EBIT 9.39 18.82
EV to EBITDA EV/EBITDA 6.95 4.36
EV to Free Cash Flow [EV/FCF] EV/FCF 13.06 17.63
EV to Market Cap EV to Market Cap 0.85 1.58
EV to Revenue EV/Rev 0.92 5.06
Price to Book Value [P/B] P/B 0.66 1.35
Price to Earnings [P/E] P/E 16.42 18.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 19.48 -2.00
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 2.86
Dividend per Basic Share Div per Share (Qtr) 0.00 0.19
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 1.94
Interest Coverage Int. cover (Qtr) 556.21 -128.90
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -52.16 -35.01
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 0.15 23.84
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.25
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -22.29 9.72
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -22.38 -444.66
EBIT Growth (1y) % EBIT 1y % (Qtr) -28.02 8.29
EBT Growth (1y) % EBT 1y % (Qtr) -27.96 -6.03
EPS Growth (1y) % EPS 1y % (Qtr) -20.98 15.59
FCF Growth (1y) % FCF 1y % (Qtr) -29.77 56.57
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 0.08 185.75
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.48 0.57
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.01
Cash Ratio Cash Ratio (Qtr) 3.26 1.23
Current Ratio Curr Ratio (Qtr) 8.63 2.70
Debt to Equity Ratio Debt/Equity (Qtr) 0.23 -0.84
Interest Cover Ratio Int Coverage (Qtr) 556.21 -128.90
Times Interest Earned Times Interest Earned (Qtr) 556.21 -128.90
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 13.40 -97.22
EBIT Margin % EBIT Margin % (Qtr) 9.82 -115.64
EBT Margin % EBT Margin % (Qtr) 9.80 -114.24
Gross Margin % Gross Margin % (Qtr) 41.10 44.76
Net Profit Margin % Net Margin % (Qtr) 6.60 -113.12